Here’s a brief excerpt of a post by CPIP Senior Scholar Eric Priest and Professor Sean Pager that was published at IPWatchdog:
As the current pandemic eviscerates jobs throughout our economy, Congress has a rare opportunity to improve the lot of one long-besieged group of workers: creators. Read more
By Camilla Hrdy
By David Ward
The U.S. Copyright Office released its long-awaited report on
In February, the U.S. Court of Appeals for the First Circuit
A group of intellectual property scholars filed 
CPIP is proud to welcome
The global COVID-19 pandemic has challenged multiple aspects of modern society in a short time. Health and public safety, education, commerce, research, arts, and even basic government functions have had to change dramatically in the space of a couple months. Some good news in all this is the response of many companies in the intellectual property (IP) industries: they are stepping up to make sure crucial information and materials are available to speed research and development (R&D) towards vaccines, therapeutics, and medical devices.
This note explains some of the concepts swirling around in the media right now, relating to medicine approval.